Application of paclitaxel in low non-cytotoxic doses supports vaccination with melanoma antigens in normal mice
- 27 March 2012
- journal article
- research article
- Published by Taylor & Francis in Journal of Immunotoxicology
- Vol. 9 (3) , 275-281
Abstract
Chemotherapeutic agents such as paclitaxel applied in ultra-low, non-cytotoxic doses were previously shown to stimulate dendritic cell activity and anti-tumor immune responses upon vaccination in mouse transplantable tumor models. However, the mechanisms of these alterations-termed chemoimmunomodulation or chemomodulation-are still not clear. This study investigated the effect of paclitaxel applied in ultra-low, non-cytotoxic doses on the efficiency of immunization of healthy C57BL/6 mice with the peptide derived from tyrosinase related protein (TRP)-2 as a model melanoma antigen. Using an IFNγ ELISPOT assay, it was found that administration of 1 mg paclitaxel/kg in combination with the peptide vaccination strongly increased the frequencies of TRP-2 specific spleen T-cells as compared to levels due to the vaccination alone. This was associated with a significant decrease in the levels of regulatory T-cells (Treg) and immature myeloid cells (known as a counterpart of myeloid derived suppressor cells [MDSC] in healthy mice). Such impairments of potential immunosuppressive cells were found to correlate with a strong increase in the amount of effector CD8+ and CD4+ T-cells in the bone marrow and spleen. Furthermore, in paclitaxel-treated mice, a significant augmentation of natural killer (NK) cell numbers in the bone marrow and their ability to produce IFNγ were observed. In addition, the level of NK-T-cells in the lymph nodes was also increased. It is suggested that paclitaxel applied in ultra-low, non-cytotoxic doses may potentially enhance the efficacy of anti-tumor vaccinations by neutralizing immunosuppressive Treg and MDSC populations in tumor-bearing hosts.Keywords
This publication has 37 references indexed in Scilit:
- Low-dose paclitaxel enhances the anti-tumor efficacy of GM-CSF surface-modified whole-tumor-cell vaccine in mouse model of prostate cancerCancer Immunology, Immunotherapy, 2011
- Chemotherapeutic agents in low noncytotoxic concentrations increase immunogenicity of human colon cancer cellsCellular Oncology, 2011
- IL‐1β regulates a novel myeloid‐derived suppressor cell subset that impairs NK cell development and functionEuropean Journal of Immunology, 2010
- T regulatory cells in cancer: recent advances and therapeutic potentialExpert Opinion on Biological Therapy, 2010
- Transforming growth‐interacting factor (TGIF) regulates proliferation and differentiation of human myeloid leukemia cellsMolecular Oncology, 2009
- Myeloid-derived suppressor cells as regulators of the immune systemNature Reviews Immunology, 2009
- Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate‐pulsed dendritic cells in a murine glioma modelInternational Journal of Cancer, 2007
- Regulatory T cells in cancerBlood, 2006
- Well-Defined Melanoma Antigens as Progression Markers for Melanoma: Insights into Differential Expression and Host Response Based on StageClinical Cancer Research, 2006
- Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells.Journal of Clinical Investigation, 1998